UK Equities

UK Multi-Cap strategy Not much has to go right for sentiment, and hopefully returns, to improve

Key points

  • Global equity markets fell in October
  • We remain focused on well capitalised businesses
  • We sold our holding in HSBC

What’s happening?

Global equity markets fell in October as cases of coronavirus continued to increase in Europe and the US. Several countries in Europe announced lockdown restrictions in an effort to slow the spread of infections. In England, local lockdowns based on a three-tier approach were later replaced by the announcement of a second national lockdown. The second lockdown will likely further impact the economy; however, some parts of the economy that closed during the first lockdown are being encouraged to remain open.

The UK market welcomed the UK and EU’s agreement to extend trade talks beyond Prime Minister Boris Johnson’s original Brexit cut-off date of the 15th October.

Portfolio positioning and performance

The strategy benefited from positions in Chemring, (global business providing a range of advanced technology products and services to the aerospace and security markets), Future (specialty media company) and Weir Group (engineering solutions provider focused on the minerals, oil and gas and power markets).

Weir Group’s share price rose on news that it had agreed to sell its’ oil & gas division to Caterpillar, a global market leader in the manufacture of construction and mining equipment. This sale leaves the company able to focus on the minerals and mining end markets, increases the focus on spares and consumables and materially reduces the debt on the company’s balance sheet.   

Not owning British American Tobacco – which fell over the month – proved positive for the strategy on a relative basis. Detractors from relative performance include HSBC, Boohoo and Clinigen.

Share price volatility was used to add to core holdings and make reductions. We sold our holding in HSBC.


The equity market is likely to remain volatile as the outcome of the US presidential election, final Brexit negotiations, ongoing central bank stimulus programmes, and the effects of COVID-19 continue to influence capital flows globally. At the time of writing, constructive sentiment is in the ascendancy following exceptionally positive results from the Pfizer (phase three) trial. This is undoubtedly a ‘good news’ story for equities and is having a dramatically positive effect on those companies seen as ‘COVID-19 losers’; for example, airlines, banks, travel and leisure), particularly those with high levels of debt, many of which have significantly fallen in value this year.     

In these volatile times, we remain focused on UK and internationally-exposed, well capitalised businesses, where the fundamental profit drivers remain entrenched and equity holders benefit from the capital allocated and risks taken by management. We continue to believe that a rewarding strategy is to actively invest in UK-listed companies that are compounding their earnings and dividends, where corporate governance is world leading, where contract law and title law are dependable, and where company management teams are permanently accessible.

Given the discount that the UK equity market trades at versus other global equity markets, even after neutralising the sectoral biases of the UK stock market, not much has to go right for sentiment, and hopefully returns, to improve.


No assurance can be given that the UK Multi-Cap Strategy will be successful. Investors can lose some or all of their capital invested. The UK Multi-Cap strategy is subject to risks including; Equity; Smaller companies risk; Liquidity risk; Investments in small and/or micro-capitalisation universe; Investments in specific countries or geographical zones.

Not for Retail distribution: This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment.  Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

This document is for informational purposes only and does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities. The strategies discussed in this document may not be available in your jurisdiction.

Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

Issued in the UK by AXA Investment Managers UK Limited, which is authorised and regulated by the Financial Conduct Authority in the UK. Registered in England and Wales No: 01431068. Registered Office: 7 Newgate Street, London EC1A 7NX. In other jurisdictions, this document is issued by AXA Investment Managers SA’s affiliates in those countries.